Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hanif Khan

Psychiatry Canton, MI Medical Doctor

NPI 1609030147 CMS profile 344585

39894 Cheviot Rd, Canton, MI 48188

Open in the dashboard

General payments

$4,104

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hanif Khan of Canton, MI is reported in the CMS Open Payments database as having received $4,104 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $955 28
2024 General $438 19
2023 General $641 14
2022 General $354 6
2021 General $44 3
2020 General $272 8
2019 General $1,400 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hanif Khan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Hanif Khan were reported at $955. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Hanif Khan Psychiatry median Middle half National median
2019 $1,400 $184 $59–$605 $163
2020 $272 $119 $36–$372 $114
2021 $44 $143 $43–$576 $132
2022 $354 $153 $50–$590 $149
2023 $641 $170 $56–$651 $160
2024 $438 $179 $57–$673 $164
2025 $955 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $1,411 34 payments
  2. Janssen Pharmaceuticals, Inc $570 12 payments
  3. Alkermes, Inc. $397 10 payments
  4. Neurocrine Biosciences, Inc. $287 8 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $280 12 payments
  6. Ironshore Pharmaceuticals Inc. $182 5 payments
  7. Vanda Pharmaceuticals Inc. $167 10 payments
  8. ITI, Inc. $139 2 payments
  9. AbbVie, Inc. $116 6 payments
  10. Lundbeck LLC $114 8 payments
  11. Other $442 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,076 128 payments
  2. Education $28 1 payment
Products named General payments · program years 2019–2025
  1. REXULTI $993 20 payments
  2. ABILIFY MAINTENA $426 14 payments
  3. ARISTADA Cns $351 8 payments
  4. ARISTADA Cns $351 8 payments
  5. ARISTADA Cns $351 8 payments
  6. ARISTADA Cns $351 8 payments
  7. ABILIFY ASIMTUFII $324 8 payments
  8. ARISTADA INITIO $315 6 payments
  9. SPRAVATO $290 4 payments
  10. INVEGA SUSTENNA $280 8 payments
  11. Other $2,097 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

772

Median for Psychiatry: 574

Drug cost

$34,242

Median for Psychiatry: $27,624

Branded share of claims

16.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 13 $17,855
Trintellix Vortioxetine Hydrobromide Brand 11 $5,510
Aripiprazole Generic 33 $1,797
Quetiapine Fumarate Generic 44 $1,227
Gabapentin Generic 56 $977
Bupropion Xl Bupropion Hcl Brand 46 $903
Hydroxyzine Pamoate Generic 32 $654
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 18 $489
Duloxetine Hcl Generic 50 $441
Risperidone Generic 31 $420

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $146
$146 13 —
VRAYLAR
  • AbbVie, Inc. $73
$73 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $57
$57 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $57
$57 — —
Auvelity
  • Axsome Therapeutics, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record